Skip to content
Acting Auditions – Lifestyle
Author:
Lupeng Pharmaceutical Ltd
Lupeng Pharmaceutical’s Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma
June 4, 2026